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Viral entryInfluenza infection is a major cause of morbidity and mortality worldwide, especially during pandemics
outbreaks. Emerging data indicate that phase II antioxidant enzyme pathways could play a role in virus-
associated inflammation and immune clearance. While Nrf2-dependent gene expression is known to modify
inflammation, a mechanistic role in viral susceptibility and clearance has yet to be elucidated. Therefore, we
utilized differentiated human nasal epithelial cells (NEC) and an enzymatic virus-like particle entry assay, to
examine the role Nrf2-dependent gene expression has on viral entry and replication. Herein, lentiviral vectors
that express Nrf2-specific short hairpin (sh)-RNA effectively decreased both Nrf2 mRNA and Nrf2 protein
expression in transduced human NEC from healthy volunteers. Nrf2 knockdown correlated with a significant
increase in influenza virus entry and replication. Conversely, supplementation with the potent Nrf2 activators
sulforaphane (SFN) and epigallocatechin gallate (EGCG) significantly decreased viral entry and replication.
The suppressive effects of EGCG on viral replication were abolished in cells with knocked-down Nrf2
expression, suggesting a causal relationship between the EGCG-induced activation of Nrf2 and the ability to
protect against viral infection. Interestingly, the induction of Nrf2 via nutritional supplements SFN and EGCG
increased antiviral mediators/responses: RIG-I, IFN-β, and MxA at baseline in the absence of infection. Our
data indicate that there is an inverse relationship between the levels of Nrf2 expression and the viral entry/
replication. We also demonstrate that supplementation with Nrf2-activating antioxidants inhibits viral
replication in human NEC, which may prove to be an attractive therapeutic intervention. Taken together,
these data indicate potential mechanisms by which Nrf2-dependent gene expression regulates susceptibility
to influenza in human epithelial cells.ed by the National Health and
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should not be construed to
ames or commercial products
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Influenza infection is a major cause of morbidity and mortality
worldwide, especially during the recent H1N1 pandemic. In the
United States alone, over 20,000 people die and over 100,000
individuals are hospitalized every year due to influenza virus-related
diseases [1–3]. Influenza viruses cause annual epidemics and
recurring pandemics with potentially severe consequences for global
public health. Despite large-scale efforts in vaccination and antiviral
therapies, the morbidity and mortality associated with influenza
infections have not significantly changed in recent years [2–4].Thelatest influenza pandemic was caused by the 2009 H1N1 virus and has
thus far resulted in 42–86 million cases worldwide [5]. Epidemiologic
studies show that high-risk groups including infants, elderly, and
immune compromised individuals are more susceptible to influenza
virus infections [6,7]. In the context of potentially pandemic
respiratory viral infections, it is important to identify and protect
susceptible subpopulations through identification of molecular
targets/pathways for therapeutic intervention. Despite the large
volumes of published data implicating age [1,7], preexisting diseases
[8], nutritional deficiencies [9–11], and an impaired innate immune
response [12–14] in influencing susceptibility to infection, the
mechanism(s) for viral susceptibility are very complex and have yet
to be elucidated.
Studies have shown that oxidative stress is associated with
increased susceptibility and severity to respiratory viral infections,
including influenza virus infections [14–17].There are a number of
factors that may influence susceptibility to influenza infections in the
human airway, specifically oxidant air pollutants, such as cigarette
smoke, diesel exhaust, and ozone [18,19]. Oxidative stress is caused by
an imbalance between the production of reactive oxygen species
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intermediates. Enzymes including phase II antioxidants, such as
hemeoxygenase 1 (HO-1), are regulated by the transcription factor
NF-E2-related factor 2 (Nrf2). The induction of these antioxidant
enzymes can prevent or slow oxidative damage to cells. Emerging
data indicate that Nrf2 plays an important role in the development of
cancer, chronic lung diseases, and defense against oxidants, as well as
host defense against respiratory viral infections [20–22]. Although it
has been shown that oxidative stress increases the severity of viral
infections, the exact mechanism as to how and why this happens and
the role of Nrf2 in these responses are not fully understood.
Since airway epithelial cells are a major source of antioxidant
enzyme production and the primary targets for influenza virus
infection and replication, it is important to determine the role of
cellular antioxidants in viral pathogenesis. On infection, epithelial
cells respond by producing numerous cytokines, immunoregulatory
molecules, and antiviral mediators, all components of the host innate
immune response. One of the principal mediators of this response is
type I interferons (IFN-α and IFN-β), which are secreted from virus-
infected cells [23,24] and are required to induce the synthesis and/or
activity of mediators involved in turning off viral replication within
the host cell. Although IFN-α/β act in an autocrine fashion to inhibit
viral replication within the infected cell, it primarily functions in a
paracrine mode by protecting neighboring cells that are not yet
infected. The most potent stimuli for type I IFN synthesis are signals
derived from a viral infection, specifically the recognition of double-
stranded RNA that is produced by viruses during their replication
process [25]. Another hallmark of influenza virus, is its sensitivity to
the inhibitory effects of IFN-inducible MxGTPases (MxA), which
significantly abrogates viral replication [26]. However, the role of
Nrf2-dependent antioxidants in the modulation of the interferon/
antiviral response in epithelial cells has not been studied.
In this study, we used our established cell culture model of
differentiated human nasal epithelial cells (NEC) [15] and generated
lentiviral vectors that expresses Nrf2-specific short hairpin (sh)-RNAs
to determine the role of Nrf2 in susceptibility to influenza A infection.
We show that Nrf2-specific shRNA effectively decreased both Nrf2
mRNA and Nrf2 protein expression in these cells, which correlated
with significantly increased viral entry and replication in transduced
human NECs. Importantly, we directly show an inverse relationship
between levels of Nrf2 expression and susceptibility to viral infection.
Interestingly, we demonstrate that enhancing Nrf2 expression via
supplementation with sulforaphane (SFN) and epigallocatechin
gallate (EGCG) increased antiviral mediators in the absence of viral
infection and also abrogated viral entry. Taken together, our data are
consistent with the conclusion that Nrf2-dependent gene expression
is an important modifier of susceptibility to influenza.
Materials and methods
Nasal epithelial cell cultures, cell lines, and growth conditions
Primary human NECs were obtained as previously described [16].
Briefly, NECs were obtained from healthy adult volunteers by gently
stroking the inferior surface of the turbinate several times with a
Rhino-Probe curette (Arlington Scientific, Arlington, TX), which was
inserted through a nasoscope. The selection criteria for recruitment of
subjects was similar to those described previously [27]. This protocol
was approved by the University of North Carolina School of Medicine
Institutional Review Board for Biomedical Research. Primary human
nasal epithelial cells were expanded to passage 2 in bronchial
epithelial growth medium (BEGM, Cambrex Bioscience Walkersville,
Inc., Walkersville, MD) and then plated on collagen-coated filter
supports with a 0.4 μm pore size (Trans-CLR; Costar, Cambridge, MA)
and cultured in a 1:1mixture of bronchial epithelial cell basic medium
(BEBM) and DMEM-H with SingleQuot supplements (Cambrex),bovine pituitary extracts (13 mg/ml), bovine serum albumin (BSA,
1.5 μg/ml), and nystatin (20 units). On confluency, all-trans retinoic
acid was added to the medium to establish air liquid interface (ALI)
culture conditions (removal of the apical medium) to promote differ-
entiation. Mucociliary differentiation was achieved after 18–21 days
post-ALI.
The HEK293T cell line was purchased from GenHunter (Nashville,
TN). Cellswere cultured inDulbecco'smodified Eagle'smedium (DMEM)
supplemented with 10% fetal bovine serum (FBS, Atlanta Biologicals,
Lawrenceville, GA) and penicillin-streptomycin (HyClone; Waltham,
MA) at 37 °C in a humidified 5% CO2 atmosphere. The BEAS-2B cell line
was derived by transforming human bronchial cells with an adenovirus
12-simianvirus40 construct [28].WeobtainedourBEAS-2Bcells fromthe
American Type Culture Collection (ATCC, Manassas, VA). BEAS-2B cells
were grown in keratinocyte basal medium (KBM) supplemented with
30 μg/ml bovine pituitary extract, 5 ng/ml human epidermal growth
factor, 500 ng/ml hydrocortisone, 0.1 mM ethanolamine, 0.1 mM phos-
phoethanolamine, and 5 ng/ml insulin.
Virus-like particle (VLP) entry assay
Construction of VLP expression plasmids
To generate the β-lactamase-M1 fusion expression plasmid
(pCAGGS-β-lacM1 PR8) the influenza A/Puerto Rico/8/34/Mount Sinai
(H1N1)M1 sequencewasPCR-amplified from theM1expression vector
pDZ-M (which was kindly provided by Dr. Adolfo Garcia-Sastre, Mount
Sinai School of Medicine) and inserted into the pCAGGS vector [29–31].
The β-lactamase gene was PCR-amplified from pcDNA3.1 and fused
N-terminally toM1within pCAGGS to create amodifiedβ-lactamase-
M1 fusion. In themodified β-lactamase, the first 24 amino acids were
excluded to remove a secretion signal and His 24 was substituted
with Asp to create an optimal Kozak consensus sequence. The
pcDNA3.1-β-lactamase construct has been described previously [32].
The influenzaA/PuertoRico/8/34/Mount Sinai (H1N1)HA(pCAGGS-HA)
and NA (pDZ-NA) overexpression vectors were generously provided by
Dr. AldolfoGarcia-Sastre andhave beendescribedpreviously [29–31,33].
Production of VLPs
To generate influenza A/PR/8/ H1N1 β-lactamaseM1VLPs (PR8
β-lacM1 VLPs), 293T cells were cotransfected with 3 μg each of
pCAGGS-HA, pDZ-NA, and pCAGGS-β-lacM1 PR8 using FuGENE HD
(Roche Applied Science, Indianapolis, IN) according to the manu-
facturer's instructions. The supernatant containing the VLPs was
collect 48 h posttransfection and clarified of floating cell debris by
centrifugation at 3000 rpm for 10 min. The VLPs were concentrated
once by low-speed centrifugation through an Amicon Ultra 100kD
centrifuge filter unit (Millipore; Billerica, MA), and the retentates
were aliquoted and stored at −80 °C.
VLP entry assay
Target cells (BEAS-2B) were seeded in either 96-well plates or
chamber slides (Lab-Tek Chamber slides, Nalge Nunc International,
Naperville, IL). After 24 h, cells werewashedwith HBSS and VLPswere
added in a total volume of 100 μl for 96-well format or 400 μl volume
for chamber slides. Cells were incubated at 37 °C for 3 h. The cells
were washed twice with HBSS to remove unbound virus and infected
cells were detected by using GeneBLAzer FRET in vivo cell-based assay
system substrate CCF2-AM according to the manufacturer's recom-
mendations (Invitrogen). Infected cells were visualized using a Nikon
C1Si laser scanning confocal microscope using suggested excitation
and emission filter settings and images were processed using the EZ-C1
FreeViewer software (Nikon Instruments,Melville, NY), or quantifiedby
using the POLARstar OPTIMA plate reader (BMG LABTECH, Inc.). To
determine the effects of Nrf2 on viral entry, modulation of Nrf2
expression was achieved by transfecting 1 μg of either a CMV-driven
human Nrf2 expression plasmid or the LV-Nrf2 lentiviral vector using
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manufacturer's instructions 24 h prior to VLP entry assay. Similarly,
endogenous Nrf2 expression was induced via supplementation with
1 μM of either SFN (Sigma-Aldrich, St. Louis, MO) or EGCG (Sigma-
Aldrich) 3 h prior to performing the entry assay.
Infection with influenza
For all experiments we used influenza A/Bangkok/1/79 (H3N2
serotype) which was propagated in 10-day-old embryonated hen's
eggs. The virus was collected in the allantoic fluid and titered by 50%
tissue culture infectious dose in Madin-Darby canine kidney cells and
hemagglutination as described before [34]. Stock virus was aliquoted
and stored at −80 °C until use. Unless otherwise indicated, for
infection about 5×105 cells were infected with approximately 128
hemagglutination units (HAU) of influenza A Bangkok 1/79, which
resulted in approximately 10% of the cells being infected with
influenza 24 h postinfection. Total RNA, total protein, basolateral
supernatants, and apical washes were collected 24 h postinfection.
Influenza virus titer
Influenza virus titers in apical washes were determined by 50%
tissue-culture infectious dose (TCID50) in Madin Darby canine kidney
(MDCK) cells and evaluated using agglutination of red blood cells as
an indicator according to a modified protocol described before [35].
Briefly, MDCK cells grown in round-bottom 96-well plates were
inoculated with virus-containing samples diluted in serum-free MEM
containing 20 μg/ml trypsin using log10 dilutions. After 3 days
incubation a suspension of human erythrocytes (0.5%) was added to
each well. Wells exhibiting hemagglutination were considered
positive and virus titers were expressed as log TCID50.
Western blotting
Cell lysates were prepared at 24 h postinfection in Passive lysis
buffer (Promega, Madison, WI) with a protease inhibitor mixture
(Cocktail Set III; Calbiochem, San Diego, CA) as well as phosphatase
inhibitors (0.5 mM NaVO4, 1 mM β-glycerophosphate) on ice for
30 min. After centrifugation, total protein concentrations were
determined by the Bradford protein assay (Bio-Rad). The cell lysates
were subjected to 12% sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS-PAGE) and transferred to nitrocellulose (Schleicher
& Schuell Biosciences, Keene, NH). Proteins were detected using specific
antibodies to Nrf2 (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA),
HO-1 (1:1000; Enzo Life Sciences, Plymouth Meeting, PA), or β-actin
(1:2000; US Biological, Swampscott, MA), and used as a loading control.
Antigen–antibody complexes were stained with anti-rabbit or anti-
mouse, horseradish peroxidase (HRP)-conjugated antibody (1:2000,
Santa Cruz Biotechnology) and detected with SuperSignal West Pico
chemiluminescent substrate (Pierce, Rockford, IL).
shRNA constructs
shRNA hairpin oligonucleotides shown below were designed by
selecting an 18-bp site from the human NFE2L2 complete mRNA (NCBI
Reference Sequence: NM_006164.3) optimized for siRNA targeting of the
NFE2L2 mRNA (LV-Nrf2) or a random 18-bp sequence (LV-scramble)
with no predicted homology to human genomic or transcript sequence:
LV-Nrf2, 5′-TCAA A T CCATGTCCTGCT-3′;
LV-scramble, 5′-ACTCTCGCCCAAGCGAGA-3′.
Single-stranded synthetic 97-bp oligonucleotides (Invitrogen
Corp., Valcencia, CA) incorporating the sense/antisense sequences in
a stem–loop motif were PCR-amplified using the primers forward,5′-AGTCACTCGAGTGCTGTTGACAGTGAG-3′; and reverse, 5′-AAGT-
CAGGATCCTCCGAGGCAGTAGG-3.′ The resulting shRNA PCR prod-
ucts were subcloned into a modified lentiviral transfer vector, GIPZ
(Thermo Fisher Scientific Inc., Birmingham, AL) between the XhoI
and the BamHI sites and the constructs were verified by fluorescent
DNA capillary sequencing. This cloning strategy nests the shRNA
fragments between 5′ and 3′ miRNA30 adaptors within the 3′ un-
translated region of a green fluorescent protein (GFP) reporter gene
under the control of a CMV promoter.
Transduction of cells with lentivirus
BEAS-2B cells were seeded in a 12-well plate in KGM media. At
24 h postseeding, media were replaced with serum-free media and
cells were infected with the lentivirus at a multiplicity of infection
(MOI) of 10 to ensure efficient infection. At 6 h postinfection complete
media were added, and cells were incubated overnight. Infection for
NECs was performed similarly, with a fewmodifications. Briefly, NECs
were infected from the apical side at anMOI of 10 andwere incubated
overnight while complete media remained unchanged on the basal-
lateral side. At 24 h postinfection, the virus was removed from the
apical surface reestablishing ALI conditions.
Lentiviral vector production and titering
HEK293T cells were cotransfected in 10 cm dishes with purified
LV-scramble or LV-Nrf2 transfer vector plasmids and lentiviral
packing mix (Open Biosystems; Huntsville, AL) according to the
manufacturer's instructions. At 16 h posttransfection, cell culture
medium was replaced with 12 ml fresh DMEM and cells were
incubated for an additional 48 h at 37 °C. Mediumwas then harvested
and detached cells were pelleted by centrifugation for 10 min at
5000g. The resulting supernatants from the individual transfections
were concentrated once by low-speed centrifugation through an
Amicon Ultra 100-kDa centrifuge filter unit (Millipore; Billerica, MA),
and the retentates were aliquoted and stored at−80 °C. To determine
viral titers, 50,000 HEK293T cells stably expressing the TetOff (rtTA3;
Clontech, Mountain View, CA) transactivator were transduced with
50 μl of lentiviral stock dilutions ranging from 1:10 to 1:781,250. Viral
titers were determined 96 h posttransduction by counting green
fluorescent colonies (encoded by the vector) by fluorescent micros-
copy and multiplying the colony count by the dilution and volume
factors.
RT-PCR
Total RNA was extracted using TRizol (Invitrogen) according to
the supplier's instruction. First-strand cDNA synthesis and real-time
RT-PCR were performed as described previously [15,34] using
commercially available primers and probes for HA, RIG-I, IFN-β, and
MxA (inventoried Taqman Gene Expression Assays) purchased from
Applied Biosystems (Foster City, CA). Nrf2 primers and probe were
previously described [36].
Fluorescent microscopy
For fluorescent analysis of the GFP reporter to identify lentiviral
transduced cells, fluorescence was visualized by a Nikon C1Si laser
scanning confocal microscope using the suggested excitation and
emission filter settings and images were processed using the EZ-C1
FreeViewer software (Nikon Instruments, Melville, NY). To view
β-lactamase activity in the virus entry assay, fluorescence was
visualized by Nikon C1Si laser scanning confocal microscope using
the suggested excitation and emission filter settings and imageswere
processed using the EZ-C1 FreeViewer software. Equal adjustments
were performed on all images to achieve maximum clarity.
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shRNA lentivirus-mediated knockdown of Nrf2 mRNA and Nrf2 protein
expression in NEC
Nrf2 is the master transcriptional regulator of the phase II
antioxidant pathways during oxidative stress. To determine the role
Nrf2 plays in susceptibility to influenza, we utilized a lentiviral vector
that expressed Nrf2-specific shRNA (LV-Nrf2) to effectively decrease
both Nrf2 mRNA and Nrf2 protein expression in transduced human
differentiated NECs from healthy volunteers, while a separate vector
expressing a scrambled nonspecific sequence was used as a negative
control. To determine the ability of the lentivirus to transduce
differentiated NECs, we infected at a multiplicity of infection of 10
and analyzed the cells for the presence of GFP expression (encoded by
the same transcript as the shRNA) 48 h postinfection (Fig. 1A).
Efficiency of the lentivirus to knock down Nrf2 gene expression was
measured by isolating total RNA from transduced cells and utilizing
real-time RT-PCR to quantitate Nrf2 mRNA transcripts normalized to
cellular β-actin expression. Nrf2 mRNA expression was significantly
knocked down by lentivirus LV-Nrf2 as compared to the control
lentivirus (LV-scramble) (Fig. 1B). Western blot analysis further
confirmed that the expression of Nrf2 protein as well as HO-1, an
Nrf2-dependent gene, was reduced, which correlated with the Nrf2
mRNA suppression (Fig. 1C).Suppression of Nrf2 gene expression enhances influenza virus replication
Next we wanted to evaluate how suppression of NRF2 affects viral
replication. Cells were infected with influenza A/Bangkok/1/79 48 h
posttransduction with the lentiviral vectors (LV-scrambled and
LV-Nrf2). Total RNA was subjected to real-time RT-PCR to quantitate
the influenza viral hemagglutinin transcript (HA) (Fig. 2A). As depicted,
we saw a significant increase in the amount of viralHAmRNAproducedFig. 1. Nrf2-specific shRNA lentivirus (LV-Nrf2) knock down Nrf2 protein expression. Cultu
lentivirus LV-Nrf2 or a GFP-scrambled control (LV-scramble). (A) NEC confocal microscopy G
to quantify Nrf2 transcripts and normalized to the expression of β-actin. (C) Cellular lysate
detect Nrf2, HO-1, and β-actin. β-Actin levels were used as internal loading controls.in the cells when Nrf2 is knocked down as compared to our control.
Similarly, by analyzing the apical washes for influenza viral titers, we
again saw a significant increase in viral replication in cells with
suppressed Nrf2 expression as compared to the control (Fig. 2B). To
validate the suppression of Nrf2 at the time of viral infection, cellular
lysates were used to analyze protein levels of both Nrf2 and HO-1
(Fig. 2C). Western blot analysis showed that expression levels of both
Nrf2 and HO-1 were significantly reduced both pre- and postinfluenza
infection. These results demonstrate that knockdown of Nrf2 signifi-
cantly increased viral replication in NECs.Induction of Nrf2 via supplementation suppresses viral replication
Previous reports have shown that Nrf2 gene expression can be
induced via antioxidant supplementation [37,38], more specifically
by the addition of a polyphenolic catechin, epigallocatechin-3-
gallate, or the organosulfur compound sulforaphane. Both com-
pounds have the ability to induce Nrf2 gene expression. Based on
initial dosing studies, we determined that a concentration of 1 and
10 μM is sufficient to detect effects of SFN and EGCG on Nrf2-
dependent gene expression in NECs in vitro with 10 μM causing
cytotoxicity (data not shown). Therefore, NECs were treated with
1 μM of either SFN or EGCG 3 h prior to infection with influenza
virus. To explore the effects of these antioxidant compounds on
viral replication, total RNA was isolated and resulting cDNAs were
quantified by RT-PCR to measure the levels of influenza HA
transcripts present. As shown in Fig. 3A, both SFN and EGCG inhibit
viral replication as marked by decreased HA gene expression. We
again collected apical washes to perform viral titer assays. Our
results show that EGCG significantly reduced viral replication, while
SFN had minimal affects (Fig. 3B).Western blots revealed that the
addition of SFN and EGCG did increase the protein levels of Nrf2
and HO-1, with EGCG enhancing Nrf2 expression (approximately 3-
fold) as compared to the vehicle (Fig. 3C). Taken together, theseres of differentiated human epithelial cells were infected at an M.O.I of 10 with shRNA
FP/shRNA (green) and nuclei (blue). (B) Total RNAwas isolated and subjected to RT-PCR
s were harvested at 48 h postinfection and were subjected to Western blot analysis to
Fig. 2. Suppression of Nrf2 gene expression enhances influenza virus replication. Cultures of differentiated human epithelial cells were infected with lentiviral vectors encoding
shRNAs LV-Nrf2 or GFP-scrambled control. At 48 h posttransduction, cells were infected with influenza A/Bangkok/1/79. (A) Total RNA was isolated and subjected to RT-PCR to
quantify Influenza HA transcripts and normalized to the expression of β-actin. (B) Apical supernatants collected 24 h postinfection were analyzed for determination of the viral titer
indicated in log TCID50. (C) Total cellular lysates were analyzed for Nrf2 and HO-1 protein expression byWestern blot. Membrane was stripped and analyzed for β-actin as a loading
control. Densitometry was used to quantitate the amounts of protein, and the numbers below the gel indicate the scramble control/experimental sample ratio. Asterisk indicates
statistical significance between test sample and control, * Pb0.05.
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tation suppresses influenza virus replication in NECs. To determine
whether the effects of EGCG on replication are indeed mediated by
Nrf2, we performed experiments whereby NECs were transduced
with either LV-Nrf2 or LV-scramble prior to treatment with EGCG.Fig. 3. Induction of Nrf2 via antioxidant supplementation suppresses viral replication. Culture
as a vehicle control. Posttreatment, cells were infected with influenza A/Bangkok/1/79. (A) T
normalized to the expression of β-actin. (B) Apical supernatants collected 24 h postinfectio
cellular lysates were analyzed for Nrf2 protein expression by Western blot. Membrane w
quantitate the amounts of protein, and the numbers below the gel indicate the scramble con
control, * Pb0.05.Fig. 4 shows that there is an Nrf2-dependent effect. The suppressive
effects of EGCG on viral replication were eliminated in cells with
knocked-down Nrf2 expression, suggesting a causal relationship
between the EGCG-induced activation of Nrf2 and the ability to
protect against viral replication.s of differentiated human epithelial cells were treated with (1 μM) SFN, EGCG, or DMSO
otal RNA was isolated and subjected to RT-PCR to quantify Influenza HA transcripts and
n were analyzed for determination of the viral titer indicated in log TCID50. (C) Total
as stripped and analyzed for β-actin as a loading control. Densitometry was used to
trol/test sample ratio. Asterisk indicates statistical significance between test sample and
Fig. 4. Effects of EGCG are dependent on Nrf2. NECs were transduced with Nrf2-shRNA
lentivirus (LV-Nrf2) or the scrambled control (LV-scramble). 48 h posttransduction,
cells were supplemented with 1 μM EGCG prior to influenza infection. Total RNA was
isolated and subjected to RT-PCR to quantify Influenza HA transcripts and normalized to
the expression of β-actin. Asterisk indicates statistical significance between test sample
and control, * Pb0.05.
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responses, protecting the cells from viral infection
To determine the potential mechanisms mediating the suppres-
sion of viral replication due to antioxidant pretreatment, we assessed
whether the innate antiviral immune response mediators were
modulated. Specifically, we analyzed the expression of interferon-β
(IFN-β), retinoic acid inducible gene I (RIG-I), and the interferon-
induced human MxA. NECs were treated with either SFN or EGCG as
stated above. Total RNA was isolated and RT-PCR was performed to
quantitate the amount of each cellular transcript independent of
influenza infection. Interestingly, we show that antioxidant supple-
mentation, specifically with EGCG, significantly increases the mRNA
expression levels of all three antiviral genes as compared to the
vehicle alone (Figs. 5A–C). These data demonstrate that, even in theFig. 5. Induction of Nrf2 via antioxidant supplementation modulates antiviral defense respo
DMSO as a vehicle control. Posttreatment, total RNAwas isolated and subjected to RT-PCR to q
expression of β-actin, (C) MxA transcripts normalized to the expression of β-actin. Asteriskabsence or prior to viral infection, addition of SFN and EGCG
significantly increases antiviral mediator expression.
Nrf2 gene expression modulates influenza virus entry
To decipher which step(s) in the virus life cycle are affected by
Nrf2 activity, we developed an enzymatic virus-like particle assay,
similar to previous reports [39]. For these experiments we utilized the
well-characterized BEAS-2B cells line. BEAS-2B cells were infected
with a virus-like particle that only expresses the hemagglutinin (HA),
neuraminidase (NA), and matrix (M) proteins along with a functional
β-lactamase reporter fusion (PR8 β-lacM1 VLP) prior to loading with
the fluorogenic substrate CCF2-AM. Fig. 6A shows the microscopy of
live cells in which the PR8 β-lacM1 VLP has entered the cells and
cleaved the CCF2-AM substrate (green), disrupting FRET, resulting in
CCF2 emission at 447 nm (blue), demonstrating the feasibility of this
assay. To determine the effects of Nrf2 expression levels on virus
entry, BEAS-2B cells were transfected with either the LV-Nrf2
lentiviral vector to knockdown Nrf2 expression or a CMV-driven
Nrf2 overexpression cDNA plasmid (CMV-Nrf2). The results show that
the suppression of Nrf2 results in a significant increase in viral entry,
but that entry can be blocked by overexpression of Nrf2 (Fig. 6B).
Finally we wanted to verify if antioxidant supplementation was
involved with the entry portion of the virus life cycle. Again, BEAS-2B
cells were pretreated with either SFN or EGCG prior to the infection
with the PR8 β-lacM1 VLP. As shown in Fig. 6C, antioxidant
supplementation significantly decreases viral entry. These data
confirm that cellular expression levels of Nrf2 play a role in viral
replication and that one mode of action is reduced viral entry.
Discussion
The exact role of oxidative stress in viral replication and/or
pathogenesis remains to be fully defined. Because airway epithelial
cells are not only a major source of antioxidant enzymes and defense
mediators in the lung but also the primary targets for influenzanses. Cultures of differentiated human epithelial cells were treated with SFN, EGCG, or
uantitate (A) IFN–β normalized to the expression of β-actin, (B) RIG-I normalized to the
indicates statistical significance between test sample and control, * Pb0.05.
Fig. 6. Nrf2 gene expression modulates influenza virus-like particle entry. To measure viral entry, (A) BEAS-2B cells were either mock-infected or infected with PR8 β-lacM1 VLP. At
2 h postinfection, cells were loaded with CCF2-AM substrate and viewed by confocal microscopy. (B) BEAS-2B were transfected with 1 μg LV-GFP, LV-Nrf2, or CMV-Nrf2 plasmid. At
24 h posttransfection, cells were infected with PR8 β-lacM1 VLP. At 2 hr postinfection, cells were loaded with CCF2-AM substrate and assayed for viral entry. (C) BEAS-2B cells were
pretreated with SFN, EGCG, or vehicle control for 1 h prior to infection with PR8 β-lacM1 VLP. At 2 h postinfection, cells were loaded with CCF2-AM substrate and assayed for viral
entry. Asterisk indicates statistical significance between test sample and control, * Pb0.05.
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mechanisms in viral pathogenesis. Nrf2 is a multifunctional tran-
scription factor that plays a role in chronic lung diseases and defense
against oxidants, as well as host defense against respiratory viral
infections [20,40–42]. Although it has been shown that oxidative
stress increases viral infection and antioxidants are thought to be
protective against influenza, the exact mechanism as to how and why
this happens and the role of Nrf2 in these responses have yet to be
elucidated. Using genetic and pharmacological manipulation of Nrf2
gene expression, our results demonstrate that in human epithelial
cells, Nrf2-dependent gene expression regulates susceptibility to
influenza at the level of antiviral mediator expression and viral entry.
The goal of this study was to understand the role Nrf2 gene
expression plays in regulating susceptibility to respiratory virus
infections, such as influenza, in fully differentiated human primary
nasal epithelial cells. Previous studies have shown that Nrf2–/– mice
developed enhanced virus-induced inflammatory and mucus cell
metaplastic changes and demonstrated decreased viral clearance after
infectionwith respiratory syncytial virus (RSV), while pretreatment of
Nrf2–/+ or Nrf2–/– mice with a potent Nrf2-activating agent sulfo-
raphane (SFN) resulted in increased levels of antioxidants including
heme oxygenase, improved viral clearance, and reduced virus-
associated inflammation [17,43]. While these studies showed a clear
association between reduced Nrf2 expression and enhanced suscep-
tibility to respiratory virus infections in mice in vivo, the cell types and
mechanisms mediating these effects remained unclear. Utilizing
human differentiated NECs transduced to express shRNAs targeting
Nrf2, our data show that Nrf2 gene expression plays a protective role
against influenza virus at the level of the epithelium. Specifically, our
data show that Nrf2 expression affects influenza virus entry and
replication in epithelial cells.
The influenza virus life cycle can be divided into four basic stages:
attachment, entry, replication, and egress which are all dependent in
part on the host cell itself, such as an infected epithelial cell.
Numerous host-cell-dependent factors can affect and control influ-
enza virus attachment and uptake by: (i) proteolytic cleavage of viral
HA by host cell-derived serine proteases, (ii) host cell-derived innateimmune defense molecules aimed at binding and neutralizing the
infectious virions, and (iii) antiviral mediators limiting viral replica-
tion and shedding of virus particles. Modification of any or several of
these factors by altering expression of Nrf2 could affect susceptibility
to infection. Our results demonstrate that increased Nrf2 activity
significantly reduces the expression of the viral HA gene as well as
influenza virus titers (Fig. 3). To dissect specific points in the virus life
cycle that could determine the role Nrf2 gene expression plays in viral
susceptibility and/or viral replication, which ultimately dictates viral
pathogenesis and outcome, we developed an enzymatic virus-like
particle assay that was adapted from previous studies using VLPs to
study HIV and Ebola virus entry [39,44,45]. Our data demonstrate that
both genetic and pharmacological manipulation of Nrf2 expression
significantly affects influenza virus entry (Fig. 6). Suppressed
expression of Nrf2 increased influenza virus entry, while increased
expression of Nrf2 reduced viral entry, thus protecting the cells from
viral infection. This report is the first to identify a mechanism of action
for Nrf2 in the context of the influenza virus life cycle.
The mechanisms through which oxidative stress and/or modified
expression of Nrf2 alters influenza virus entry are not clear. Based on
previous reports, we hypothesize that increased viral entry and
subsequent replication seen in cells with reduced Nrf2 expression/
activity are mediated through the activation of host cellular
transmembrane proteases. As indicated above, regulated proteolysis
is required for the spread/propagation of many human viruses,
including human immunodeficiency virus (HIV), Nipah, Ebola, severe
acute respiratory syndrome coronavirus (SARS-CoV), metapneumo-
viruses, and influenza [46–50]. Previous studies have demonstrated
the importance of protease-specific cellular proteases/antiproteases
involved in influenza infection, which include transmembrane
protease serine 2 (TMPRSS2), human airway trypsin-like protease
(HAT), and secretory leukocyte proteinase inhibitor (SLIP) [51,52].
The expression of these proteases in the lung is necessary for cleav-
age of the viral HA surface protein, thus allowing viral fusion and
entry into the host cell. Studies have shown a correlation between
inflammation and oxidative stress which leads to altered expression
of these proteases/antiproteases. Specifically, HAT has been shown to
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particularly in asthmatics [53,54], and a murine study showed that
SLPI gene expression was increased in Nrf2-deficient mice which led
to increased inflammation and demonstrated a balance between
oxidative stress and protease expression [52]. These studies combined
with our data presented here lead us to hypothesize that oxidative
stress, which is propagated via decreasedNrf2 gene expression, causes
an increase in serine protease activity, culminating in increased
efficiency of HA cleavage and thus increased viron entry, which we
demonstrated in Fig. 6.
Interestingly, our results demonstrate that supplementation with
SFN and to a greater extent EGCG not only increased Nrf2 protein
levels but also induced the expression of three well-characterized
antiviral response genes which include RIG-I, IFN-β, and MxA (Fig. 5).
It is noteworthy that the increased expression of these antiviral genes
was induced via supplementation with EGCG in the absence of a viral
infection. It is known that infection and replication of viruses result in
the accumulation of intracellular ssRNA and dsRNA in the host cell,
which triggers multiple host response mechanisms, including the
expression of type I INFs, MxA, and RIG-I. Viral infections normally
induce the production of type I IFNs, which in turn activate the
synthesis of numerous interferon-stimulated genes (ISGs). ISGs
collectively induce an “antiviral state” in the host cell itself as well
as the neighboring cells, thus limiting viral replication in these cells.
One of these ISGs is MxA, which belongs to a small family of GTPases
that have been shown to inhibit viral replication. MxA has also
displayed antiviral activity toward influenza A virus [55]. Another
IFN-inducible gene is RIG-I, which is a cytosolic DExD/H box-
containing RNA helicase that interacts with dsRNA and augments
interferon production in response to a viral infection [56,57]. We
demonstrate that treatment with EGCG, in the absence of a viral
infection, increased the mRNA expression levels of RIG-I, which
appear to be in contrast to a recent study which showed that EGCG
suppresses Rig-I signaling [58]. This study identified, in a small
molecule screen, that EGCG binds to RIG-I and reported that at
certain concentrations EGCG efficiently binds to RIG-I and, while not
interfering with RIG-I's ability to bind RNA, does suppresses RIG-I
signaling. However, these studies were performed in the HEK293T
cell line, which could contribute to the somewhat conflicting results.
Based on our observations, we hypothesize that EGCG up-regulates
the expression of these antiviral geneswhich proactively protects the
cells prior to viral infection by inducing and “antiviral protective
state.” It is possible that IFN-β, RIG-I, and MxA genes may contain an
Nrf2 binding site in their promoter regions, and the induction of Nrf2
would thus increase the transcription of these antiviral genes.
However, at least to our knowledge, essential Nrf2 binding sites
have not been identified in promoters of any of the genes listed above
and studies examining gene expression profiling of Nrf2 in mice did
not report differences in the antiviral or interferon responsive genes
[40,59]. It is conceivable that the effects of SFN and EGCG on IFN-β,
RIG-I, andMxA expression areNrf2 independent or that the effects are
species and/or cell-type specific.
SFN and EGCG have been shown to have potent antioxidant
capacities, in part by inducing the expression of a number of
antioxidant enzymes [60]. In vitro and in vivo studies have shown
that these supplements potently induce the expression of phase II
antioxidant genes, which was associated with Nrf2-electrophile
response element (EpRE) signaling [37,61–63]. The mechanism of
activation for Nrf2 induction involves serine/threonine phosphoryla-
tion, leading to increased nuclear accumulation and binding to the
EpRE [64]. Whether and how activation of Nrf2-dependent gene
expression is involved in its potential antiviral effects are not known.
Our data show that EGCG and to a lesser extent SFNmodifies influenza
replication in human respiratory epithelial cells at 1 μM concentration
and that the effects of EGCG on viral replication are abolished in cells
with knocked-down Nrf2 expression (Fig. 2). It is likely that higherconcentrations of SFN would yield significant effects on viral
replication. These observations are similar to previous mouse in vivo
studies showing that supplementation with SFN only reduced RSV
infection in Nrf2+/+ mice but not Nrf2−/− mice [17]. Previous studies
have indicated that EGCG directly binds influenza virus and therefore
prevents attachment and entry into host cells [65,66]. However, these
studies were conducted in MDCK cells, which are not a natural host
cell for influenza and require addition of exogenous proteases to
achieve viral entry [65]. Our data demonstrate that supplementation
of differentiated NECs with either SFN or EGCG from the basolateral
side (to eliminate direct interaction with the virus during infection)
significantly decreases influenza virus entry and replication and that
these effects were dependent on Nrf2 (Fig. 4).
Nrf2 status may influence susceptibility to viral exacerbations in
specific subpopulations. It has been reported that Nrf2 protects the
lung against oxidative stress [20,40], and recent data describe
functional polymorphisms within the Nrf2 gene in humans [67].
Nrf2 has been identified as a susceptibility gene that increases the risk
of acute lung injury, and other reports have also identified a role for
Nrf2 in pulmonary diseases associated with oxidative stress, such as
chronic obstructive pulmonary disease (COPD) and asthma [68,69].
Viral infections have been shown to exacerbate these diseases.
Understanding how Nrf2 orchestrates cellular defense mechanisms
may provide insight to the development of novel interventions and
preventative strategies targeted against oxidative airway diseases.
Investigating antioxidant supplementation treatment along with
potential inhibitors of influenza-activating type II transmembrane
serine proteases (TTSPs) could be important additions to the current
antiviral therapy which includes targeting neuraminidase and the ion
channel M2. Influenza infection remains a major global public health
concern, and understanding the mechanisms that modulate suscep-
tibility to influenza infection can have vast impacts on morbidity,
mortality, and ultimately infection outcome.
In summary, this work provides insight into identifying and
understanding new molecular pathways in which Nrf2 gene expres-
sion potentially protect cells from viral infection. Our work demon-
strates that activation of the Nrf2-dependent gene expression prior to
influenza abrogates viral entry and replication. We also found that the
transcription factor Nrf2 plays a critical role in dictating susceptibility
to viral infection at the level of the epithelium. We have shown that
nutritional supplementation, with SFN or EGCG, not only increases
Nrf2 levels but also increases the expression of multiple antiviral
mediators in the absence of a viral infection. We hypothesize that
induction of these antiviral mediators in turn initiates an “antiviral
state” priming the cells against a viral infection, thus limiting virus
entry and replication. Previous studies have demonstrated that in
humans orally administered SFN at doses of 200 μmol yields peak
plasma levels reaching about 2 μmol/L [70]. Similarly, previous studies
determining the pharmacokinetics of EGCG in humans reported that a
single dose of 1.5 mmol orally administered EGCG achieved peak
plasma concentrations averaging 1.3 μmol/L [71]. Thus, levels of SFN
and EGCG shown here to have antiviral effects are clinically feasible.
Further studies aimed at using orally administered SFN or EGCG may
provide greater insights into potential novel antiviral therapeutic
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